This company listing is no longer active
Yourgene Health Valuation
Is YGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of YGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate YGEN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate YGEN's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for YGEN?
Key metric: As YGEN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is YGEN's PS Ratio? | |
|---|---|
| PS Ratio | 0.6x |
| Sales | UK£29.67m |
| Market Cap | UK£16.45m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.1x |
| Enterprise Value/EBITDA | -11.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does YGEN's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.5x | ||
EMVC EMV Capital | 6.5x | 49.2% | UK£11.7m |
IHC Inspiration Healthcare Group | 0.4x | 13.6% | UK£14.1m |
AGL ANGLE | 18.3x | 51.4% | UK£37.1m |
OBI Ondine Biomedical | 24.9x | 66.0% | UK£22.9m |
YGEN Yourgene Health | 0.6x | n/a | UK£16.4m |
Price-To-Sales vs Peers: YGEN is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (16.4x).
Price to Sales Ratio vs Industry
How does YGEN's PS Ratio compare vs other companies in the GB Medical Equipment Industry?
| 4 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 3.1x | 6.4% | |
YGEN Yourgene Health | 0.6x | n/a | US$20.48m |
SPEC INSPECS Group | 0.3x | 5.5% | US$73.06m |
IHC Inspiration Healthcare Group | 0.4x | 13.6% | US$17.80m |
| 4 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 3.1x | 22.6% | |
YGEN Yourgene Health | 0.6x | n/a | US$20.48m |
Price-To-Sales vs Industry: YGEN is good value based on its Price-To-Sales Ratio (0.6x) compared to the UK Medical Equipment industry average (2.8x).
Price to Sales Ratio vs Fair Ratio
What is YGEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate YGEN's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Guerbet
€341.1m
Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
0ELV
€27.05
7D
-9.8%
1Y
51.3%
Fagron
€1.4b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
0HNZ
€18.61
7D
-1.4%
1Y
6.7%
Axogen
US$548.8m
Develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.
0HKD
US$12.49
7D
1.2%
1Y
112.1%